Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study

Park, Hye Yun; Kang, Danbee; Shin, Sun Hye; Yoo, Kwang Ha; Rhee, Chin Kook; Suh, Gee Young; Kim, Hojoong; Shim, Young Mog; Güallar, Eliseo; Cho, Juhee; Kwon, O Jung

doi:10.1136/thoraxjnl-2019-213732

Cited by 80 publications

(76 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A link between microbial infections and the development of cancer has been demonstrated. COPD is an important independent risk factor for lung cancer ( 47 , 48 ). Chronic inflammation is a key characteristic of COPD ( 49 ).…”

Section: Microorganisms Inflammation and Cancermentioning

confidence: 99%

“…The isolation and characterization of individual circulating tumor cells (CTCs)-associated white blood cells (WBCs) (CTCs–WBCs) as well as corresponding cancer cells within each CTCs–WBCs cluster showed that neutrophils and CTCs interact within the blood, and this interaction promotes cell cycle progression, which enhances the possibility of tumor metastasis of CTCs ( 61 ). COPD is at high risk of lung cancer ( 48 ). Non-typeable Haemophilus influenzae (NTHi) colonization can increase the frequency of exacerbations of COPD ( 62 ).…”

Section: Microorganisms Inflammation and Cancermentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary Micro-Ecological Changes and Potential Microbial Markers in Lung Cancer Patients

et al. 2021

View full text Add to dashboard Cite

The relationship between the microbiome and disease has been investigated for many years. As a highly malignant tumor, biomarkers for lung cancer are diverse. However, precision of these biomarkers has not yet been achieved. It has been confirmed that lung microecology changes in lung cancer patients compared with healthy individuals. Furthermore, the abundance of some bacterial species shows obvious changes, suggesting their potential use as a microbial marker for the detection of lung cancer. In addition, recent studies have confirmed that inflammation, immune response, virulence factors, and metabolism may be potential mechanisms linking the microbiome with carcinogenesis. In this review, microbiome studies of lung cancer, potential mechanisms, potential microbial markers, and the influence of the microbiome on the diagnosis and treatment of lung cancer are summarized, providing theoretical strategies for the diagnosis and treatment of lung cancer.

show abstract

Section: Microorganisms Inflammation and Cancermentioning

confidence: 99%

Section: Microorganisms Inflammation and Cancermentioning

confidence: 99%

Pulmonary Micro-Ecological Changes and Potential Microbial Markers in Lung Cancer Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…COPD and the ICS user have clear operational de nitions (6,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24).…”

Section: Operational De Nitionsmentioning

confidence: 99%

COPD is not associated with a poor prognosis in COVID-19

Kim

Park

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) is a worldwide pandemic. The effect of underlying chronic obstructive pulmonary disease (COPD) on COVID-19 is controversial. We set this study to examine the clinical outcomes of COVID-19 according to the underlying COPD.Methods: COVID-19 patients were assessed using nationwide health insurance data. COPD patients were operationally defined. Comorbidities were evaluated by using the modified Charlson Comorbidity Index (mCCI) which excluded the factors of COPD from conventional CCI scores. Baseline characteristics and clinical outcomes of COVID-19, such as mortality, hospital length of stay (LOS), and intensive care unit (ICU) admission, were assessed. Subgroup analysis about the effect of inhaled corticosteroid of COPD patients on COVID-19 was performed.Results: COPD group were older (71.3±11.6 vs. 47.7±19.1, p < 0.001) and have higher CCI scores (2.6±1.9 vs. 0.8±1.3, p < 0.001) than non-COPD group. Mortality was higher in COPD groups than in non-COPD group (22.9% vs. 3.2%, p < 0.001). The ICU admission rate and hospital LOS were not significantly different between the two groups. In univariate analysis, ages, male sex, mCCI, socioeconomic status, and underlying COPD were associated with mortality. In multivariate analysis, underlying COPD was not associated with mortality after adjusted. On the other hand, other variables are still associated with mortality. Older ages (odds ratio [OR] 1.12; 95% confidence interval [CI] 1.11–1.14; p < 0.001), male sex (OR 2.29; 95% CI 1.67–3.12; p < 0.001), higher mCCI (OR 1.30; 95% CI 1.20–1.41; p < 0.001), and medical aid insurance (OR 1.55; 95% CI 1.03–2.32; p = 0.035) were associated with mortality of COVID-19. Underlying COPD was also not associated with hospital LOS and ICU admission rates in the adjusted analyses. In the subgroup analysis, there was no significant difference between the ICS user and nonuser including mortality and hospital LOS. In the adjusted analyses, the use of ICS in COPD patients was not associated with mortality and hospital LOS in COVID-19.Conclusions: Mortality, hospital LOS, and ICU admission rate were not associated with underlying COPD in COVID-19.

show abstract

“…The potential causes include genetics, notably the EGFR mutation [ 4 ] in Asian females. Other factors are residential radon [ 5 ], chronic obstructive pulmonary disease [ 6 ] and being underweight [ 7 ]. The effects of alcohol consumption are disputed: it seemed to have a positive effect on the disease in Spanish women [ 8 ], but a larger meta-analysis suggested that abstinence (as opposed to moderate consumption of wine or spirits) was not beneficial [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Research on lung cancer and its funding, 2004–2018

Begum¹,

Urquhart²,

Lewison³

et al. 2020

ecancer

View full text Add to dashboard Cite

Although smoking is declining in high-income countries, the relative burden from its most well-known consequence, lung cancer, continues to increase, especially in low-income countries. We examined the amount, types, geographical origins and funding of research on lung cancer as revealed by papers in the Web of Science over the 15 years, 2004–2018. The annual number of lung cancer research papers increased over the study period from 2,157 to 8,202, but as a percentage of all biomedical research in Western Europe and North America they only accounted for one-eighth of the percentage of the disease burden. Lung cancer increased its share of cancer research from 4.4% to 6.5%, mainly because of the greatly expanded output from China in 2014–2018 which published almost one-third of the world’s total on a fractional count basis. For almost all other countries, their lung cancer presence in cancer research has declined over the 15 years. However, only 15% of the Chinese papers were co-authored internationally and its research was focussed on treatment rather than prevention. Support for lung cancer research is primarily from the government rather than charity. There is therefore an urgent need to increase support for lung cancer research, and for more international collaboration, especially in low-income countries where the disease burden is growing rapidly, and in neglected domains, such as screening and palliative care.

show abstract

Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study

Cited by 80 publications

References 12 publications

Pulmonary Micro-Ecological Changes and Potential Microbial Markers in Lung Cancer Patients

Pulmonary Micro-Ecological Changes and Potential Microbial Markers in Lung Cancer Patients

COPD is not associated with a poor prognosis in COVID-19

Research on lung cancer and its funding, 2004–2018

Contact Info

Product

Resources

About